Winter Capital Partners is a private equity and venture capital firm established in 2015 and based in Moscow City, Russia. The firm specializes in mid to late venture and growth capital investments, primarily in consumer technology, financial services, education, healthcare, and digital health sectors. It engages in global investments, typically allocating between $0.5 million and $5 million for venture capital and $10 million to $100 million for private equity. Winter Capital Partners generally takes minority stakes in venture capital investments and can hold both minority and controlling stakes in private equity deals. Additionally, the firm offers advisory services to its portfolio companies, leveraging its market expertise to support growth.
ivi.ru Media Ltd. operates an online video and cinema platform in Russia, providing a wide range of content that includes movies, television series, shows, cartoons, and music videos. Founded in 2007 and based in Moscow, the platform offers a video-on-demand service that enhances the traditional television experience by allowing users to access content through a secure, scalable, and portable online player. ivi creates opportunities for both independent content producers and mainstream broadcasters by enabling live streaming channels and expanding audience reach. The company focuses on delivering licensed professional content, allowing users to enjoy premium video offerings at no cost.
Home Market
Venture Round in 2014
Home Market is a discount retail chain based in Moscow, Russia, specializing in non-food items. The company operates fixed-price stores that offer a diverse range of products, including household chemicals, cosmetics, clothing, and stationery. By providing access to a wide variety of lifestyle and daily usage products, Home Market aims to ensure affordability and convenience for its customers.
Petrovax
Venture Round in 2014
Petrovax is a leading Russian company engaged in research, development and production of innovative pharmaceuticals. The company owns a portfolio of original products, including vaccines, immune system medicines and prolonged biotech drugs. The company operates a modern GMP-compliant facility in the Moscow Region with annual capacity in liquid forms well above 150mn doses. Petrovax was one of the first Russian companies to receive a European GMP certificate and remains one of the few exporters of locally developed and produced drugs into the EU and the Middle East. Today Petrovax is the largest vaccines exporter in Russia. In 2020 Petrovax deeply engaged in COVID-19 Vaccine and Medication research and development, becoming the first Russian company to receive phase 3 clinical trial approvals for both.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.